Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XDEMVY vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
XDEMVY (lotilaner ophthalmic solution) is a gamma-aminobutyric acid (GABA)-gated chloride channel antagonist. It inhibits the GABA-gated chloride channels in Demodex mites, leading to paralysis and death of the mites.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Treatment of Demodex blepharitis
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
1 drop in each eye once daily in the evening for 6 weeks.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life of approximately 4-6 hours; clinically, steady-state is reached within 24-36 hours.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Lotilaner is metabolized via cytochrome P450 (CYP) enzymes, primarily CYP3A4, and to a lesser extent CYP2C9 and CYP2C19.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Primary renal excretion as unchanged drug and metabolites; ~70% in urine. Biliary/fecal excretion accounts for ~25%.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Approximately 90% bound to serum albumin and alpha-1-acid glycoprotein.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Volume of distribution is 0.35 L/kg, indicating limited extravascular distribution.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral bioavailability is approximately 85%; food may delay absorption but does not affect extent.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
No dosage adjustment is recommended for patients with renal impairment.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
No dosage adjustment is recommended for patients with hepatic impairment.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Safety and efficacy have not been established in pediatric patients.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
No dosage adjustment is recommended based on age; clinical studies included patients ≥65 years, and no overall differences in safety or efficacy were observed.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
None
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Contains preservative benzalkonium chloride, which may cause eye irritation and is adsorbable by soft contact lenses. Patients should remove contact lenses prior to administration and wait at least 15 minutes before reinserting.,Use with caution in patients with known hypersensitivity to any component of the product.,Not for injection. For topical ophthalmic use only.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Hypersensitivity to lotilaner or any component of the formulation.
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
No clinically significant food interactions reported.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no teratogenic effects were observed at exposures up to 5 times the human exposure at the recommended ophthalmic dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Unknown if excreted in human milk. No data on M/P ratio. Caution advised; consider developmental benefits of breastfeeding vs potential drug exposure.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
No pharmacokinetic studies in pregnancy; no dose adjustment recommended.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
XDEMVY (lotilaner ophthalmic solution) 0.25% is the first FDA-approved treatment for Demodex blepharitis. Administer one drop in each affected eye twice daily (approximately 12 hours apart) for 6 weeks. Shake well before use. Contact lenses should be removed prior to instillation and may be reinserted 15 minutes after dosing. Avoid touching the dropper tip to any surface to prevent contamination.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Use exactly as prescribed: one drop in each eye twice daily for 6 weeks.,Shake the bottle well before each use.,Remove contact lenses before applying and wait at least 15 minutes before reinserting.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,If you miss a dose, apply as soon as you remember, but if it is close to the next dose, skip the missed dose and resume normal schedule.,Common side effects may include temporary stinging or blurred vision after application.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XDEMVY vs ALFENTANIL, answered by our medical review team.
XDEMVY is a Antiparasitic Agent that works by XDEMVY (lotilaner ophthalmic solution) is a gamma-aminobutyric acid (GABA)-gated chloride channel antagonist. It inhibits the GABA-gated chloride channels in Demodex mites, leading to paralysis and death of the mites.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XDEMVY and ALFENTANIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XDEMVY is: 1 drop in each eye once daily in the evening for 6 weeks.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XDEMVY and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XDEMVY is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no teratogenic effects were observed at exposures up to 5 times the human exposure at the. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.